Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Anal Biochem ; 337(2): 235-45, 2005 Feb 15.
Article in English | MEDLINE | ID: mdl-15691503

ABSTRACT

PedvaxHIB is a pediatric vaccine that protects children from severe disease caused by the gram-negative bacterium Haemophilus influenzae type b (Hib). The vaccine is made by chemically conjugating Hib capsular polysaccharide to the outer membrane protein complex of Neisseria meningitidis. The protein-conjugated vaccine has proven to be extremely effective in preventing invasive Hib disease in infants and young children. This paper presents the nuclear magnetic resonance (NMR) methodology for the quantitative characterization of derivatized polysaccharide and its validation closely following ICH guidelines. The assay has been shown to be precise and accurate (relative standard deviation [RSD]

Subject(s)
Bacterial Outer Membrane Proteins/chemistry , Haemophilus Vaccines/chemistry , Haemophilus influenzae type b/chemistry , Haemophilus influenzae type b/metabolism , Polysaccharides, Bacterial/chemistry , Magnetic Resonance Spectroscopy , Molecular Structure , Reproducibility of Results , Sensitivity and Specificity , Substrate Specificity , Vaccines, Conjugate/chemistry
3.
Anal Biochem ; 336(2): 262-72, 2005 Jan 15.
Article in English | MEDLINE | ID: mdl-15620891

ABSTRACT

Purified capsular polysaccharide preparations from Streptococcus pneumoniae that are used for vaccine production typically contain residual levels of C-polysaccharide (C-Ps). Residual C-Ps is typically found in one of two forms, either chemically linked to the capsular polysaccharide (bound) or present by itself (free). Two analytical methods have been developed and applied to determine the relative percentages of the two C-Ps forms present in various capsular polysaccharide preparations. Both methods differentiate the two forms of C-Ps according to the difference of their hydrodynamic sizes. One method is based on labeling C-Ps with a fluorescent tag and separating the two forms of C-Ps by high-performance size exclusion chromatography with on-line refractive index and fluorescence detection, and the other method is based on measuring self-diffusion rates of the two forms of C-Ps by nuclear magnetic resonance (NMR) and quantifying each form with deconvolution. Both methods were evaluated for relative accuracy, precision, and ease of application, and they were found to provide comparable results for a large number of pneumococcal polysaccharide preparations. These analyses, combined with other quantitative NMR measurement of total C-Ps in the polysaccharide powder, provide a more refined means of evaluating the amount of each form of C-Ps in polysaccharide preparations targeted for vaccine production.


Subject(s)
Bacterial Capsules/chemistry , Polysaccharides, Bacterial/analysis , Polysaccharides, Bacterial/chemistry , Streptococcus pneumoniae/chemistry , Bacterial Capsules/metabolism , Carbohydrate Sequence , Chromatography, High Pressure Liquid , Magnetic Resonance Spectroscopy , Molecular Sequence Data , Polysaccharides, Bacterial/metabolism , Streptococcus pneumoniae/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...